Juno Therapeutics announced that it has raised $134 million in a private placement pushing funding past $300 million in less than a year. “We believe the winner in this space is going to be about doing great science and to do that you have to be well-resourced,” says Juno chief executive Hans Bishop to Forbes. Juno is a Seattle-based biotech company focused on developing adoptive T-cell therapies aimed at curing a broad range of cancers. Juno brings together two world leaders in this type of therapy, Fred Hutchinson Cancer Research Center in Seattle and Memorial Sloan-Kettering Cancer Center in New York, along with renowned pediatric partner Seattle Childrens Research Institute.
Posted on: Tue, 05 Aug 2014 17:12:50 +0000
Trending Topics
Recently Viewed Topics
© 2015